Skip to main content

View Resource

Published

Immunogenicity and safety of self-amplifying mRNA COVID-19 vaccine (ARCT-2303), with or without co-administration of seasonal inactivated influenza vaccine in adults: a phase 3, randomised, controlled, observer-blind, multicentre study.
Giles ML. eClinicalMedicine 2025;:https://doi.org/10.1016/j.eclinm.2025.103428.
[A recently licenced self-amplifying mRNA (sa-mRNA) COVID-19 vaccine induces a robust, broad, and long-lasting immune response, extending the arsenal of efficacious COVID-19 countermeasures. We conclude that ARCT-2303 induces a robust immune response against the vaccine variant of SARS-CoV-2 and can be co-administered with licenced influenza vaccines in adults with no impact on the safety or immunogenicity of either vaccine.]
Freely available online
Age Groups
Adults
Older People
Conditions and Lifestyle Factors
Coronavirus Infections
Influenza
Settings
Population Health
Staff Groups
Immunisation
Public Health Doctor
Public Health Specialist